683 related articles for article (PubMed ID: 32497804)
21. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
Henrich TJ; Hatano H; Bacon O; Hogan LE; Rutishauser R; Hill A; Kearney MF; Anderson EM; Buchbinder SP; Cohen SE; Abdel-Mohsen M; Pohlmeyer CW; Fromentin R; Hoh R; Liu AY; McCune JM; Spindler J; Metcalf-Pate K; Hobbs KS; Thanh C; Gibson EA; Kuritzkes DR; Siliciano RF; Price RW; Richman DD; Chomont N; Siliciano JD; Mellors JW; Yukl SA; Blankson JN; Liegler T; Deeks SG
PLoS Med; 2017 Nov; 14(11):e1002417. PubMed ID: 29112956
[TBL] [Abstract][Full Text] [Related]
22. Short Communication: Assessing Estimates of HIV Incidence with a Recent Infection Testing Algorithm That Includes Viral Load Testing and Exposure to Antiretroviral Therapy.
Kim AA; Rehle T
AIDS Res Hum Retroviruses; 2018 Oct; 34(10):863-866. PubMed ID: 29926735
[TBL] [Abstract][Full Text] [Related]
23. The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy.
Huntington S; Thorne C; Newell ML; Anderson J; Taylor GP; Pillay D; Hill T; Tookey PA; Sabin C;
AIDS; 2015 Nov; 29(17):2269-78. PubMed ID: 26544700
[TBL] [Abstract][Full Text] [Related]
24. Towards achieving the 90-90-90 HIV targets: results from the south African 2017 national HIV survey.
Marinda E; Simbayi L; Zuma K; Zungu N; Moyo S; Kondlo L; Jooste S; Nadol P; Igumbor E; Dietrich C; Briggs-Hagen M
BMC Public Health; 2020 Sep; 20(1):1375. PubMed ID: 32907565
[TBL] [Abstract][Full Text] [Related]
25. Multivariate analysis of covariates of adherence among HIV-positive mothers with low viral suppression.
Nsubuga-Nyombi T; Sensalire S; Karamagi E; Aloyo J; Byabagambi J; Rahimzai M; Nabitaka LK; Calnan J
AIDS Res Ther; 2018 Mar; 15(1):9. PubMed ID: 29604955
[TBL] [Abstract][Full Text] [Related]
26. Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa.
Petersen M; Balzer L; Kwarsiima D; Sang N; Chamie G; Ayieko J; Kabami J; Owaraganise A; Liegler T; Mwangwa F; Kadede K; Jain V; Plenty A; Brown L; Lavoy G; Schwab J; Black D; van der Laan M; Bukusi EA; Cohen CR; Clark TD; Charlebois E; Kamya M; Havlir D
JAMA; 2017 Jun; 317(21):2196-2206. PubMed ID: 28586888
[TBL] [Abstract][Full Text] [Related]
27. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.
Milloy MJ; Kerr T; Buxton J; Rhodes T; Krusi A; Guillemi S; Hogg R; Montaner J; Wood E
J Acquir Immune Defic Syndr; 2012 Apr; 59(4):393-9. PubMed ID: 22134149
[TBL] [Abstract][Full Text] [Related]
28. Immunologic and virological response to ART among HIV infected individuals at a tertiary hospital in Ghana.
Obiri-Yeboah D; Pappoe F; Baidoo I; Arthur F; Hayfron-Benjamin A; Essien-Baidoo S; Kwakye-Nuako G; Ayisi Addo S
BMC Infect Dis; 2018 May; 18(1):230. PubMed ID: 29783953
[TBL] [Abstract][Full Text] [Related]
29. Determinants of viral load rebound on HIV/AIDS patients receiving antiretroviral therapy: results from South Africa.
Shoko C; Chikobvu D
Theor Biol Med Model; 2018 Jul; 15(1):10. PubMed ID: 30008270
[TBL] [Abstract][Full Text] [Related]
30. True durability: HIV virologic suppression in an urban clinic and implications for timing of intensive adherence efforts and viral load monitoring.
Benator DA; Elmi A; Rodriguez MD; Gale HB; Kan VL; Hoffman HJ; Tramazzo S; Hall K; McKnight A; Squires L
AIDS Behav; 2015 Apr; 19(4):594-600. PubMed ID: 25369887
[TBL] [Abstract][Full Text] [Related]
31. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
Teira R; Vidal F; Muñoz-Sánchez P; Geijo P; Viciana P; Ribera E; Domingo P; Castaño M; Martínez E; Roca B; Puig T; Estrada V; Deig E; Galindo MJ; de la Fuente B; Lozano F; Montero M; Muñoz-Sanz A; Sanchez T; Terrón A; Romero-Palacios A; Lacalle JR; Garrido M; Suárez-Lozano I;
HIV Med; 2017 Mar; 18(3):196-203. PubMed ID: 27476742
[TBL] [Abstract][Full Text] [Related]
32. HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study.
Desta AA; Woldearegay TW; Futwi N; Gebrehiwot GT; Gebru GG; Berhe AA; Godefay H
BMC Infect Dis; 2020 Jan; 20(1):4. PubMed ID: 31898535
[TBL] [Abstract][Full Text] [Related]
33. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
[TBL] [Abstract][Full Text] [Related]
34. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
[TBL] [Abstract][Full Text] [Related]
35. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
Kousignian I; Abgrall S; Duval X; Descamps D; Matheron S; Costagliola D;
J Acquir Immune Defic Syndr; 2003 Sep; 34(1):50-7. PubMed ID: 14501793
[TBL] [Abstract][Full Text] [Related]
36. Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study.
Small W; Milloy MJ; McNeil R; Maher L; Kerr T
AIDS Res Ther; 2016; 13():26. PubMed ID: 27462360
[TBL] [Abstract][Full Text] [Related]
37. Non-persistence to antiretroviral therapy among adults receiving HIV medical care in the United States.
Nyaku M; Beer L; Shu F
AIDS Care; 2019 May; 31(5):599-608. PubMed ID: 30309269
[TBL] [Abstract][Full Text] [Related]
38. Incidence of Health Facility Switching and Associations With HIV Viral Rebound Among Persons on Antiretroviral Therapy in Uganda: A Population-based Study.
Rosen JG; Ndyanabo A; Nakawooya H; Galiwango RM; Ssekubugu R; Ssekasanvu J; Kim S; Rucinski KB; Nakigozi G; Nalugoda F; Kigozi G; Quinn TC; Chang LW; Kennedy CE; Reynolds SJ; Kagaayi J; Grabowski MK
Clin Infect Dis; 2024 Jun; 78(6):1591-1600. PubMed ID: 38114162
[TBL] [Abstract][Full Text] [Related]
39. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.
Lima VD; Bangsberg DR; Harrigan PR; Deeks SG; Yip B; Hogg RS; Montaner JS
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):460-5. PubMed ID: 20838225
[TBL] [Abstract][Full Text] [Related]
40. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.
Giron LB; Papasavvas E; Yin X; Goldman AR; Tang HY; Palmer CS; Landay AL; Li JZ; Koethe JR; Mounzer K; Kostman JR; Liu Q; Montaner LJ; Abdel-Mohsen M
mBio; 2021 Feb; 12(1):. PubMed ID: 33622719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
